PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
72.03%
Positive net income growth while Medical - Pharmaceuticals median is negative at -2.80%. Peter Lynch would view it as a strong advantage vs. struggling peers.
48.66%
D&A growth under 50% of Medical - Pharmaceuticals median of 3.81%, or significantly exceeding it. Jim Chanos would suspect overcapacity or misallocated capex if new assets do not pay off quickly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
446.54%
Working capital of 446.54% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
35.05%
Inventory growth of 35.05% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
No Data
No Data available this quarter, please select a different quarter.
1037.17%
Under 50% of Medical - Pharmaceuticals median of 2.56% if negative or far above if positive. Jim Chanos would sense potential red flags or large tie-ups in these rarely monitored accounts.
86.60%
Growth of 86.60% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
801.91%
Operating cash flow growth exceeding 1.5x Medical - Pharmaceuticals median of 12.25%. Joel Greenblatt would see a strong operational advantage vs. peers.
-18.08%
CapEx declines yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.68%
We reduce “other investing” yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-19.20%
Reduced investing yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-20.39%
Debt repayment yoy declines while Medical - Pharmaceuticals median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.